Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

Heart

Volumn 98, Issue 15, 2012, Pages 1153-1159

  Urbano Moral, Jose Angel ^a   Lopez Haldon, Jose Eduardo ^a   Fernandez, Monica ^a   Mancha, Fernando ^a   Sanchez, Angel ^a   Rodriguez Puras, Maria Jose ^a   Villa, Manuel ^a   Lopez Pardo, Francisco ^a   Diaz De La Llera, Luis ^a   Valle, Juan Ignacio ^a   Martinez, Angel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B; GLUCOSE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84863802480     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301636     Document Type: Article

References (50)

1. Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993;22:1763-72. (Pubitemid 23359629)
2. Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb). N Engl J Med 1997;336:1621-8.
3. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177-89. (Pubitemid 35215244)
4. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-201. (Pubitemid 35215245)
5. Murdoch DR, Love MP, Robb SD, et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. Eur Heart J 1998;19:1829-35. (Pubitemid 28556653)
6. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999;159:29-34. (Pubitemid 29044116)
7. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an International forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82. (Pubitemid 30167013)
8. St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96:3294-9. (Pubitemid 27513397)
9. Deedwania P, Kosiborod M, Barrett E, et al American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610-19. (Pubitemid 351440650)
10. Hassan AK, Bergheanu SC, Hasan-Ali H, et al. Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2009;103:779-84.
11. Cerisano G, Pucci PD, Sulla A, et al. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction. Am J Cardiol 2007;99:651-6.
12. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006;114:1020-7. (Pubitemid 44358878)
13. Takahashi T, Anzai T, Yoshikawa T, et al. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction - role of neurohormones and cytokines. Int J Cardiol 2003;88:257-65. (Pubitemid 36513664)
14. Vanderheyden M, Goethals M, Verstreken S, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-54. (Pubitemid 39647609)
15. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-7. (Pubitemid 35244737)
16. Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984;1:1264-7. (Pubitemid 14111082)
17. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8. (Pubitemid 30128815)
18. Wahab NN, Cowden EA, Pearce NJ, et al ICONS Investigators. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002;40:1748-54. (Pubitemid 35341952)
19. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005;111:3078-86. (Pubitemid 40847785)
20. Svensson AM, McGuire DK, Abrahamsson P, et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005;26:1255-61. (Pubitemid 41435454)
21. Yang SW, Zhou YJ, Hu DY, et al BEAMIS Study Group. Association between admission hypoglycaemia and in-hospital and 3-year mortality in older patients with acute myocardial infarction. Heart 2010;96:1444-50.
22. Worthley MI, Shrive FM, Anderson TJ, et al. Prognostic implication of hyperglycemia in myocardial infarction and primary angioplasty. Am J Med 2007;120:643.e1-7.
23. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7. (Pubitemid 36044395)
24. Cochet A, Zeller M, Lalande A, et al. Utility of Cardiac Magnetic Resonance to assess association between admission hyperglycemia and myocardial damage in patients with reperfused ST-segment elevation myocardial infarction. J Cardiovasc Magn Reson 2008;10:2.
25. Ishihara M, Inoue I, Kawagoe T, et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J 2003;146:674-8. (Pubitemid 37281713)
26. Greig D, Corbalán R, Castro P, et al. Admission hyperglycemia and mortality of ST segment elevation myocardial infarction. Rev Med Chil 2010;138:1109-16.
27. Cruz-Gonzalez I, Chia S, Raffel OC, et al. Hyperglycemia on admission predicts larger infarct size in patients undergoing percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Diabetes Res Clin Pract 2010;88:97-102.
28. Bauters C, Ennezat PV, Tricot O, et al REVE Investigators. Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. Eur Heart J 2007;28:546-52. (Pubitemid 47355520)
29. Anantharaman R, Heatley M, Weston CF. Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target? Heart 2009;95:697-703.
30. Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J 2002;143:696-702. (Pubitemid 34454704)
31. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-21.
32. Cerisano G, Pucci PD, Valenti R, et al. Comparison of the usefulness of Doppler-derived deceleration time versus plasma brain natriuretic peptide to predict left ventricular remodeling after mechanical revascularization in patients with ST-elevation acute myocardial infarction and left ventricular systolic dysfunction. Am J Cardiol 2005;95:930-4. (Pubitemid 40487740)
33. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203. (Pubitemid 24203680)
34. Bolognese L, Cerisano G, Buonamici P, et al. Influence of infarct-zone viability on left ventricular remodeling after acute myocardial infarction. Circulation 1997;96:3353-9. (Pubitemid 27513405)
35. Klip IT, Voors AA, Anker SD, et al; OPTIMAAL investigators. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 2011;97:892-8.
36. Uusimaa P, Risteli J, Niemelä M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997;96:2565-72. (Pubitemid 27451347)
37. Bishop JE, Greenbaum R, Gibson DG, et al. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol 1990;22:1157-65. (Pubitemid 20378828)
38. Manhenke C, Orn S, Squire I, et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2011;150:277-82.
39. Squire IB, Evans J, Ng LL, et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004;10:328-33. (Pubitemid 39092685)
40. Wagner DR, Delagardelle C, Ernens I, et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006;12:66-72. (Pubitemid 43267754)
41. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008;29:2116-24.
42. Gaudron P, Eilles C, Kugler I, et al. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87:755-63. (Pubitemid 23070806)
43. Fertin M, Hennache B, Hamon M, et al. Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 2010;106:1410-16.
44. Jolly SS, Shenkman H, Brieger D, et al GRACE Investigators. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2011;97:197-202.
45. Gabriel AS, Martinsson A, Wretlind B, et al. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med 2004;15:523-8. (Pubitemid 40164483)
46. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53. (Pubitemid 38856961)
47. Ørn S, Manhenke C, Ueland T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009;30:1180-6.
48. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006;47:962-8.
49. Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J 2006;152:1161-7. (Pubitemid 44854795)
50. Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction-the smoker's paradox revisited. Am Heart J 2005;150:358-64. (Pubitemid 41116264)